Biodesix® Named Innovative Company of the Year at 2016 IQ Awards
Biodesix won the BizIQ award, 2016 Innovative Company of the Year.
×
254 Results
Biodesix won the BizIQ award, 2016 Innovative Company of the Year.
GeneStrat blood-based mutation testing for advanced lung cancer offers significant advantages for patients and their treating physicians over standard tissue testing, which can delay treatment.
Humana, Medical Mutual of Ohio and Preferred One independently determined and published a policy stating that VeriStrat can be considered medically necessary for patients with (NSCLC)
Dr. Heinrich Roder, will present the company’s approach and recent results for a blood test stratifying patients for immunotherapy benefit on Thursday, March 10, at Molecular Med Tri-Conference.
Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.
Biodesix has selected Norgen Biotek to supply sample preparation products for its EML4-ALK blood test.
VeriStrat® Test identifies patients with squamous cell carcinoma of the lung who are more likely to have improved survival on Afatinib therapy.
Independent Study Data supports clinical use of Biodesix’s blood-based tests at CHEST conference.
Biodesix's VeriStrat test identifies T790M-mutated advanced non-small cell lung cancer patients who are more likely to have improved progression-free survival on third generation EGFR-TKI therapy
Biodesix will present data from three studies at SITC's annual meeting.
Biodesix to present data from three studies indicating the utility of blood-based diagnostic tests at the AACR annual meeting
Biodesix raised $22 million through the sale of series F preferred stock and other securities.
Biodesix CEO David Brunel will present a corporate overview on Deep Phenotyping, Machine Learning to Precision Medicine at the Leerink Partners Conference
Multi-institutional data supporting clinical use of Biodesix blood tests was presented at the IASCL Chicago thoracic conference
Biodesix press release: Wellmark BCBS of Iowa and South Dakota provides coverage for VeriStrat® Test
The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision
Biodesix presents data at the World Lung Conference showing the ability to stratify lung cancer patients treated with immunotherapy
Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference
Data from an independent study demonstrated the clinical utiity of Biodesix' VeriStrat and GeneStrat tests.
Horizon Blue Cross Blue Shield (BCBS) of New Jersey has determined that the VeriStrat® proteomic test is now considered a medically necessary benefit for members with advanced NSCLC.
Heinrich Roder will speak at the 6th International Conference on Bioinformatics and Systems Biology
Biodesix raises an additional $7 million in series F financing.
With positive coverage decisions from BCBS Florida and HCSC, 200 million Americans now have insurance coverage for VeriStrat testing.